Further trials of nifurtimox in mucocutaneous leishmaniasis

At a dosage level of 8 to 10 mg/kg body-weight daily for 120 days nifurtimox was associated with clinical healing of cutaneous leishmaniasis in five of eight patients. At a dosage level of 20 mg/kg body-weight daily for 10 days in six of 10 patients the skin ulcer healed. Results and the reasons why both schemes are impracticable are briefly discussed.